An editorial by PharmExec.com editors, says United States-based healthcare executives are not interested in expanding patient-reported outcome measures. Executives are skeptical of health economics and outcomes researchers that drug manufacturers pay to conduct studies, according to a report by Burlington, Mass.-based InVentiv Health.
Of respondents, 92 percent are not interested in expanding patient-reported outcome measures in clinical trials.
Concerning HEOR measures, drug companies often fund research, leading many payers to questions its validity. But, approximately 70 percent of executives are confident in HEOR measures when a neutral organization or institution supports the measure.